Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFS-ADA Lentiviral Gene Therapy for ADA-SCID
NCT01852071Phase 2Completed
- Sponsor
- University of California, Los Angeles
- Start
- Aug 2013
- Primary completion
- Aug 2018
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of simoladagene autotemcel in severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), sponsored by University of California, Los Angeles. Started Aug 2013; status: completed.
02
Drugs
simoladagene autotemcel
03
Conditions
severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID)
Beyond the preview
Go deeper on NCT01852071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01852071.